Clinical Trials Browser

Phase 2 × Lung Neoplasms × aflutinib × Clear all

NCT04671303 2025-05-11

To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer

Phase 2 Completed

Lung Neoplasms

NCT06585644 2024-09-05

A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms